← Home / VANDA PHARMACEUTICALS INC. (VNDA)
Stock Analysis
VANDA PHARMACEUTICALS INC. (VNDA)
VNDA
VNDA · Market data
5.10 -1.54%
Track VNDA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when VNDA price is:
52W Range Position
17%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:45 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Moderate / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
5.90
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
6
●
Financial Results
HIGH
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
• Fanapt ® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76% • NEREUS TM (tradipitant) launched via nereus.us , an innovative direct-to-consumer platform – the first new prescription medicine in more than 40 years for the prevention of vomiting i...
8-K Filing • SEC EDGAR
What's Driving VNDA?
📈 Technical recovery is improving
Momentum is Neutral. Watch 5.90 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
33.4
Price Chart
VNDA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$306.7M
Company size
EV
$260.1M
Debt-adjusted value
P/E
-1.3
Not meaningful
P/S
1.4
Low sales multiple
P/B
1.1
Low book multiple
EV/Sales
1.2
Low sales multiple
EV/EBIT
-1.6
Not meaningful
P/FCF
-2.4
Not meaningful
FCF Yield
-41.51%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Moderate
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
51.72M
≈ Moderate
📈 Net Income
-48.57M
↘ Negative
🧮 EPS (Basic)
-0.82
↘ Negative
VANDA PHARMACEUTICALS INC.
Related Opportunities